Organisation paid for research Program year 2025 Source: CMS Open Payments

Dallas VA Research Corp

Neither a doctor nor a teaching hospital

Research payments

$558,459

58 payments

Through program year 2025, Dallas VA Research Corp is reported as receiving $558,459 in research payments, across 58 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $28,082 4
2024 Research $123,909 9
2023 Research $37,229 7
2022 Research $94,137 6
2021 Research $74,741 6
2020 Research $67,190 7
2019 Research $133,170 19

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $387,126 33 payments
  2. Genentech, Inc. $66,796 7 payments
  3. Amgen Inc. $48,357 3 payments
  4. ViiV Healthcare Company $22,740 3 payments
  5. Ironwood Pharmaceuticals, Inc $14,235 7 payments
  6. Organon LLC $11,000 1 payment
  7. Medtronic Vascular, Inc. $8,205 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC $113,585 9 payments
  2. A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma $100,369 7 payments
  3. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation $84,861 9 payments
  4. Atezolizumab and Bevacizumab Tiragolumab in 1L Unresectable HCC PTS $66,796 7 payments
  5. Galactic-Hf $44,812 2 payments
  6. Dapagliflozin in Acute Decompensated Heart Failure $34,300 3 payments
  7. A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (MATTERHORN) $27,741 3 payments
  8. Effects of Abacavir and Tenofovir on Bone Microarchitecture $22,740 3 payments
  9. A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $17,555 1 payment
  10. C3718-301 $14,235 7 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $11,000 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record